Heart failure & cardiomyopathies
Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials
Authors' conclusion
In patients with symptomatic obstructive HCM, mavacamten monotherapy was associated with improvements in clinical and echocardiographic outcomes, with a similar safety profile to that observed with mavacamten plus background HCM therapy in clinical trials.
Study context
- Population
- Patients with obstructive hypertrophic cardiomyopathy (HCM) from EXPLORER-HCM, the EXPLORER cohort of MAVA-LTE, VALOR-HCM and EXPLORER-CN
- Comparison
- mavacamten monotherapy vs mavacamten plus beta-blockers or mavacamten plus calcium-channel blockers, by background therapy use at the time of mavacamten initiation
Methodological detailspooled
- Pooled
Main finding
As reported in the abstract
Left ventricular outflow tract gradients and symptoms
- Mavacamten monotherapy was associated with improvements in left ventricular outflow tract gradients and symptoms
- Descriptive comparisons with patients receiving mavacamten plus beta-blockers or calcium-channel blockers suggested broadly similar trends in efficacy and adverse event rates
- Descriptive comparisons
Safety
Reductions in left ventricular ejection fraction · baseline to week 128
- Reductions in left ventricular ejection fraction across treatment groups
- ≤8.8%
Original publication
Mavacamten monotherapy in obstructive hypertrophic cardiomyopathy: An integrated analysis of phase 3 clinical trials. Am Heart J. Published 24 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it